VIARTIS

 

 

 PARKINSON'S DISEASE NEWS

 

 

 

 

 

Parkinson's Disease News covers all significant new research, reports, books, and resources concerning Parkinson's Disease. Articles are chosen on the basis of their medical significance or potential interest. Our overwhelming priority is the facts, regardless of whether they contradict prevailing views or vested interests. Analysis and further information are provided either to explain the background or implications, or to balance misleading claims. If you notice errors or inadequacies, or dispute what is written, or want to propose articles, please e-mail [email protected].

                                          

 

6th September 2013 - New research

SAFINAMIDE CLINICAL TRIAL RESULTS

European Journal of Neurology [2013] September 11 [Epub ahead of print] (A.H.Schapira, F.Stocchi, R.Borgohain, M.Onofrj, M.Bhatt, P.Lorenzana, V.Lucini, R.Giuliani, R.Anand)  Complete abstract

Safinamide is believed to have both dopaminergic and non-dopaminergic actions, including the inhibition of MAO-B and inhibition of glutamate release. It is undergoing  Phase III clinical development as a once-daily add-on to dopamine agonists for the treatment of early Parkinson's Disease. For more information go toSafinamide.

In a one year clinical trial people with Parkinson's Disease received 100mg or 200mg Safinamide daily. They were assessed according to how long it was before they had to increase their dopamine agonist dose or add another Parkinson's Disease treatment. People receiving 100 mg/day safinamide experienced a significantly lower rate of intervention compared with placebo, of 25% instead of 51% and a small delay before the need to increase other Parkinson's Disease treatments of 9 days.

In a previous study of once daily dosages of 50mg to 100mg Safinamide improved Parkinson's Disease symptoms after six months and reduced "off" time when added on to the use of existing Parkinson's Disease treatments. However, the reduction in "off" time in comparison to the use of a placebo was minimal. The increase in "on" time beyond that of a placebo was only 40 minutes for 50mg safinamide, and 50 minutes for 100mg safinamide. For more information go to the Complete abstract. For a printable version of this article click here. For more news go to Parkinson's Disease News.

 

E-MAIL NOTIFICATION : If you would like to be notified by e-mail when any new articles are added to Parkinson's Disease News,  please merely e-mail [email protected] with the message "subscribe".  No form of identity is required.  E-mail addresses are not used for any other purpose.

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 


 
2006-2013  Viartis
 
2015-01-04 15:36:12
 
[email protected]